Acquired Company
Imara merged with Enliven Therapeutics, with the combined company completing the merger and beginning trading under ELVN, on February 23–24, 2023.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado. Show more
6200 Lookout Road, Boulder, CO, 80301, United States
Start AI Chat
Market Cap
1.629B
52 Wk Range
$13.30 - $30.22
Previous Close
$27.45
Open
$27.68
Volume
871,344
Day Range
$27.62 - $28.92
Enterprise Value
690M
Cash
477.6M
Avg Qtr Burn
-13.28M
Insider Ownership
8.27%
Institutional Own.
-
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ELVN-001 Details Chronic Myeloid Leukemia | Phase 1 Data readout | |
ELVN-002 w/ trastuzumab +/- chemotherapeutic agents Details Cancer, Metastatic breast cancer, Metastatic colorectal cancer | Failed Discontinued | |
ELVN-002 monotherapy Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Failed Discontinued |
